- Revive Therapeutics (RVVTF, Financial) to explore Bucillamine's potential in cancer treatment.
- Partnership with U.S. University Cancer Institute and Defence R&D Canada for research support.
- Research funded by NIH and other government entities, boosting market opportunities.
Revive Therapeutics Ltd. (OTCQB: RVVTF), a specialty life sciences company, is collaborating with a prominent researcher from a U.S. University Cancer Institute to explore the potential use of Bucillamine as a cancer treatment. The focus is on enhancing anti-tumor effects in patients with advanced solid tumors.
This initiative will be incorporated into a broader study supported by funding from the National Institutes of Health (NIH) and other government entities. The research aims to capitalize on Bucillamine's role as a thiol donor, which could neutralize reactive oxygen species and replenish reduced glutathione in the tumor microenvironment (TME), thus amplifying anti-tumor effects.
The study builds on Revive's existing partnerships, including one with Defence R&D Canada – Suffield Research Centre, focusing on Bucillamine for nerve agent exposure treatment. This multi-faceted approach highlights the compound's potential for various medical applications.
Chief Executive Officer Michael Frank expressed enthusiasm about collaborating with a leading U.S. cancer institute to validate Bucillamine's anti-inflammatory and antioxidant properties, addressing key factors that contribute to cancer progression. The study reflects Revive's commitment to discovering novel therapeutic strategies for challenging health conditions.
